Full text is available at the source.
Lancet (London, England)···
Semaglutide and heart health in people with obesity and existing heart failure: results from the SELECT trial
Updated
Abstract
Among 17,604 patients, semaglutide significantly reduced major adverse cardiovascular events (MACE) by a hazard ratio of 0.72 in those with heart failure compared to placebo.
- Semaglutide improved all measured cardiovascular outcomes in patients with heart failure compared to those without.
- Patients with heart failure with reduced ejection fraction showed a hazard ratio of 0.65 for MACE with semaglutide.
- In patients with heart failure with preserved ejection fraction, the hazard ratio for MACE was 0.69 with semaglutide treatment.
- Higher clinical event rates were observed in patients with heart failure with reduced ejection fraction than in those with preserved ejection fraction.
- Serious adverse events occurred less frequently in patients treated with semaglutide than in those receiving placebo, regardless of heart failure subtype.
Simplified
BACKGROUND: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure.
METHODS: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/mor greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. 2
FINDINGS: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m(5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all p>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. 2interaction
INTERPRETATION: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group.
FUNDING: Novo Nordisk.
Related papers
Apr '24
Semaglutide compared to placebo in people with obesity-related heart failure with normal pumping function: combined analysis of two clinical trials
top 1% journal
cited by 306 papers
randomized controlled trial
Sep '24
Semaglutide compared to placebo in heart failure patients with mildly reduced or preserved heart pumping function: combined analysis of four clinical trials
top 1% journal
cited by 230 papers
randomized controlled trial
Jan '25
Semaglutide's effects on heart failure with preserved pumping and type 2 diabetes in obesity, varying by starting blood sugar levels
top 1% journal
cited by 16 papers
randomized controlled trial
Sep '24
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Normal Pumping Function
top 1% journal
cited by 32 papers
randomized controlled trial
Jun '24
Semaglutide and Heart Failure Severity in Obesity-Related Heart Failure with Normal Pumping Function
top 1% journal
cited by 46 papers
randomized controlled trial
Jun '24
Semaglutide’s effects on obesity-related heart failure with preserved pumping function vary by sex
top 1% journal
cited by 44 papers
randomized controlled trial
May '24
Semaglutide and diuretic use in obesity-related heart failure with normal pumping function: combined analysis of two clinical trials
top 1% journal
cited by 74 papers
randomized controlled trial
Mar '21
Weekly Semaglutide 2.4 mg for Adults with Overweight or Obesity and Type 2 Diabetes: A Controlled Clinical Trial
top 1% journal
cited by 1,112 papers
randomized controlled trial
Sep '24
Semaglutide's effects on heart failure in people with diabetes and kidney disease in the FLOW trial
top 1% journal
cited by 96 papers
randomized controlled trial
Apr '17
Weekly semaglutide compared to daily sitagliptin added to diabetes pills in type 2 diabetes over 56 weeks: a safety and effectiveness trial
top 1% journal
cited by 420 papers
randomized controlled trial